Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models

Cancer Gene Therapy

Volumn 20, Issue 1, 2013, Pages 17-24

  Passer, B J ^a   Cheema, T ^a   Wu, S ^a   Wu, C L ^a   Rabkin, S D ^a   Martuza, R L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angiogenesis; Combination therapy; IL 12; Microtubule disrupting agents; Oncolytic HSV 1; Prostate cancer

Indexed keywords

CD31 ANTIGEN; INTERLEUKIN 12; ONCOLYTIC HERPES VIRUS; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC GENE THERAPY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GENE THERAPY; CELL KILLING; CELL LINE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MICROTUBULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; STROMA; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; COMBINED MODALITY THERAPY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-12; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROSTATIC NEOPLASMS; SIMPLEXVIRUS; TUBULIN MODULATORS; TUMOR BURDEN; VERO CELLS; VINBLASTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

HUMAN HERPESVIRUS 1; MUS; SIMPLEXVIRUS;

EID: 84871975005     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.75     Document Type: Article

References (44)

1. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856.
2. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 939-943.
3. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002; 9: 967-978.
4. Kuruppu D, Tanabe KK. Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol Ther 2005; 4: 524-531.
5. Kaur B, Chiocca EA, Cripe TP. Oncolytic HSV-1 virotherapy: Clinical experience and opportunities for progress. Curr Pharm Biotechnol 2012; 13: 1842-1851.
6. Wong RJ, Patel SG, Kim S, DeMatteo RP, Malhotra S, Bennett JJ et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 2001; 12: 253-265.
7. Wong RJ, Chan MK, Yu Z, Ghossein RA, Ngai I, Adusumilli PS et al. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 2004; 10: 4509-4516.
8. Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL. Enhanced therapeutic efficacy of IL-12, but not GM-CSF expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther 2005; 13: 253-265.
9. Varghese S, Rabkin SD, Nielsen PG, Wang W, Martuza RL. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin Cancer Res 2006; 12: 2919-2927.
10. Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R, Martuza RL. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res 2007; 67: 9371-9379.
11. Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 2000; 60: 1111-1116.
12. Mitola S, Strasly M, Prato M, Ghia P, Bussolino F. IL-12 regulates an endothelial cell-lymphocyte network: Effect on metalloproteinase-9 production. J Immunol 2003; 171: 3725-3733.
13. Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther 2009; 7: 551-560.
14. Lin SF, Gao SP, Price DL, Li S, Chou TC, Singh P et al. Synergy of a herpesoncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin Cancer Res 2008; 14: 1519-1528.
15. Huang B, Sikorski R, Kirn DH, Thorne SH. Synergistic anti-tumor effects between oncolyticvaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther 2011; 18: 164-172.
16. Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R et al. Synergistic effects of oncolyticreovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer 2011; 11: 221.
17. Radhakrishnan S, Miranda E, Ekblad M, Holford A, Pizarro MT, Lemoine NR et al. Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts. Hum Gene Ther 2010; 10: 1311-1325.
18. Oberg D, Yanover E, Adam V, Sweeney K, Costas C, Lemoine NR et al. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin Cancer Res 2010; 16: 541-553.
19. Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res 2009; 15: 2594-2601.
20. Wong RJ, Patel SG, Kim S, DeMatteo RP, Malhotra S, Bennett JJ et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 2001; 12: 253-265.
21. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents. J Infect Dis 1988; 158: 602-614.
22. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
23. Passer BJ, Wu C-L, Wu S, Rabkin SD, Martuza RL. Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. Gene Ther 2009; 16: 1477-1482.
24. Kanthou C, Tozer GM. Tumour targeting by microtubule-depolymerizing vascular disrupting agents. Expert Opin Ther Targets 2007; 11: 1443-1457.
25. Folkman J. Anti-angiogenesis: New concept for therapy of solid tumors. Ann Surg 1972; 175: 409-416.
26. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674.
27. Folkman J. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286.
28. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15-R24.
29. Liu R, Varghese S, Rabkin SD. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer Res 2005; 65: 1532-1540.
30. Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X et al. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res 2006; 12: 6791-6799.
31. Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL et al. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther 2006; 14: 789-797.
32. Zhang W, Fulci G, Buhrman JS, Stemmer-Rachamimov AO, Chen JW, Wojtkiewicz GR et al. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol Ther 2012; 1: 37-45.
33. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 155-168.
34. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. JNCI 1995; 87: 581-586.
35. Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999; 5: 1612-1621.
36. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61: 517-525.
37. Penfold MET, Armati P, Cunningham AL. Axonal transport of herpes simplex virions to epidermal cells: Evidence for a specialized mode of virus transport and assembly. Proc Natl Acad Sci USA 91: 6529-6533.
38. Avitabile E, Di Gaeta S, Torrisi MA, Ward PL, Roizman B, Campadelli-Fiume G. Redistribution of microtubles and golgi apparatus in herpes simplex virus-infected cells and their role in viral exocytosis. J Virol 1995; 69: 7472-7782.
39. Kotaskis A, Pomeranz LE, Blouin A, Blaho JA. Microtubule reorganization during herpes simplex virus type I infection facilitates nuclear localization of VP22, a major virion tegment protein. J Virol 2001; 75: 8697-8711.
40. Lin S-F, Gao SP, Price DL, Li S, Chou T-C, Singh P et al. Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin Cancer Res 2008; 14: 1519-1528.
41. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-409.
42. Gettman MT, Pacelli A, Slezak J, Bergstralh EJ, Blute M, Zincke H et al. Role of microvessel density in predicting recurrence in pathologic stage T3 prostatic adenocarcinoma. Urology 1999; 54: 479-485.
43. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM et al. Randomized, double-blind, placebo-controlled phaseIII trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castrationresistant prostate cancer: CALGB 90401. J Clin Oncol 2012; 30: 1534-1540.
44. Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001; 20: 79-86.